论文部分内容阅读
目的:研究多药耐药基因在白血病中表达的情况及意义。方法:应用逆转录—多聚酶链反应(RT- PCR)和免疫细胞化学APAAP 方法检测了50 例白血病患者多药耐药( mdr - 1) 基因及P- 糖蛋白(Pgp) 的表达情况并进行分析研究。结果: mdr- 1 及Pgp 的表达与患者的年龄有关, 50 岁以上患者的阳性率显著增高( P< 0.05, P<0 .01) 。未经治疗的初诊患者mdr- 1 的阳性率显著低于反复化疗的患者( P< 0 .05) 。Pgp 表达与临床疗效的总符合率为72 .5 % , 低于m dr - 1 的表达与临床疗效的总符合率86 % 。两项指标联合检测, 其临床疗效总符合率最佳91.3 % 。结论:m dr - 1 及Pgp 是两个良好的临床多药耐药监测指标,尤以二者联合应用为佳。
Objective: To study the expression and significance of multidrug resistance gene expression in leukemia. Methods: The expression of multidrug resistance (mdr-1) gene and P-glycoprotein (Pgp) in 50 leukemia patients was detected by reverse transcription-polymerase chain reaction (RT-PCR) and immunocytochemistry APAAP method. the study. RESULTS: The expression of mdr-1 and Pgp was related to the age of the patients, and the positive rate of patients over the age of 50 was significantly higher (P<0.05, P<0.01). The positive rate of mdr-1 in the untreated newly diagnosed patients was significantly lower than that in patients undergoing repeated chemotherapy (P<0.05). The total coincidence rate of Pgp expression and clinical efficacy was 72.5%, which was lower than the 86% of the overall agreement between the expression of mdr-1 and clinical efficacy. Combined detection of the two indicators, the best clinical compliance rate of 91.3%. Conclusion: m dr - 1 and Pgp are two good clinical multidrug resistance monitoring indicators, especially the combination of the two is better.